Scott Johnson
Pulmonary Disease · Pinehurst, NCNPI 1598739179
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (57.5%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. 31 manufacturers reported payments, led by Mylan Specialty L.p. at 56.5% of the total. Reporting peaked in 2020 at $16,663 and has fallen 99.9% since, to $17 in 2024. Among pulmonary disease clinicians in NC with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 248 payments — averaging $98.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Mylan Specialty L.p.$14K
- Boehringer Ingelheim$8K
- Actelion Pharmaceuticals US, Inc.$517
- GSK$480
- Sunovion Pharmaceuticals Inc.$286
- AstraZeneca$231
- plus $2K from 25 others
What the payments were for
- Consulting fees$5,16021%
- Speaking & faculty fees$14,02657%
- Travel & lodging$1,2775%
- Food & beverage$3,92816%
- Education$40%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Mylan Specialty L.p. | 44 | $13,791 |
| Boehringer Ingelheim | 17 | $7,559 |
| Actelion Pharmaceuticals US, Inc. | 26 | $517 |
| GSK | 37 | $480 |
| Sunovion Pharmaceuticals Inc. | 20 | $286 |
| AstraZeneca | 16 | $231 |
| Regeneron Healthcare Solutions, Inc. | 9 | $181 |
| Grifols USA, LLC | 7 | $175 |
| Bayer | 9 | $153 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 7 | $104 |
| Philips North America LLC | 4 | $88 |
| Shire North American Group Inc | 6 | $87 |
| Sanofi | 5 | $84 |
| Lilly USA, LLC | 6 | $76 |
| Insmed, Inc. | 5 | $71 |
| Novartis | 4 | $69 |
| Genentech USA, Inc. | 4 | $67 |
| Bristol Myers Squibb | 3 | $66 |
| United Therapeutics Corporation | 3 | $57 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $46 |
| Daiichi Sankyo Inc. | 2 | $31 |
| Astellas Pharma US Inc | 1 | $24 |
| Gilead | 2 | $23 |
| Paratek Pharmaceuticals, Inc. | 1 | $22 |
| CSL Behring | 1 | $19 |
| Azurity Pharmaceuticals, Inc. | 1 | $17 |
| Jazz Pharmaceuticals Inc. | 1 | $16 |
| Circassia Inc. | 1 | $15 |
| Advanced Respiratory, Inc | 1 | $15 |
| La Jolla Pharmaceutical Company | 1 | $13 |
| Merck | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$24,394 in reported general payments places this provider in the 90th percentile of 393 pulmonary disease providers in North Carolina.
Other pulmonary disease in Pinehurst
- Michael PritchettPinehurst$1.3M
- Bradley IcardPinehurst$299K
- Scott SkiboPinehurst$229K
- Adam BelangerPinehurst$96K
- Michael WertGreensboro$412K
- Eugene BleeckerWinston Salem$357K
- James DonohueChapel Hill$271K
- Eric MeltzerDurham$262K
- Daniel BreaultWilmington$257K
- Jill OharWinston Salem$226K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.